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After more than two decades of research, the latest published
studies regarding the protective eﬀects of anti-inﬂammatory
drugs in Parkinson’s disease (PD) indicate that only a subset
of nonsteroidal anti-inﬂammatory drugs (NSAIDs) may be
eﬃcient in decreasing the risk of PD. In particular, recent
epidemiology studies and meta-analysis have shown that,
amongtheseNSAIDS,theinhibitorsoftheenzymecyclooxy-
genase(COX)werethemostpotentcompoundsreachingthe
highest rate of PD prevention. These data clearly support a
COX-speciﬁc mechanism of neuroprotection and reinforce
the idea that neuroinﬂammation in PD comprises speciﬁc
features that should be unraveled. Such that knowledge
should help the development of speciﬁc drugs targeting in-
ﬂammatory mediators.
Several clinical trials currently ongoing have focused
their goals in evaluating in vivo potential imaging biomark-
ers for inﬂammatory changes in neurodegeneration. [18F]
FEPPA and [(11) C] PBR28 are being evaluated for their
capacity in detecting neuroinﬂammation by single pho-
ton emission computed tomography (SPECT). This is an
important step regarding the safe monitoring of neuroin-
ﬂammation in patients. If successful, these in vivo imaging
methods will be valuable not only to determine precisely
the right therapeutic window but also to accurately measure
the biological outcomes of neuroprotective treatments. Most
importantly, this also means that the inﬂammatory compo-
nent of PD is having signiﬁcant attention among researchers
and it will probably be assumed in the clinical scenario in
the coming years.Inaddition, there are numerous preclinical
trials testing the protective eﬀects of anti-inﬂammatory
drugs in animal models of PD and hopefully some of them
will soon be brought into Phase I trials. However, further
research and new perspectives are needed to understand the
speciﬁc aspects of inﬂammation in PD.
In the present special issue, we present 9 review articles
that explore new insights into the inﬂammatory reaction
associated with PD. D. Litteljohn et al. show an excel-
lent review of how the toxin-based models of PD have
contributed signiﬁcantly to the study of the mechanisms
underlying neuroinﬂammatory processes in Parkinsonism
and outline the role of TNF-α and IFN-γ, two cytokines
critically involved in glial cell activation and dopaminergic
d e g e n e r a t i o n .T h e n ,T .F a r o o q u ia n dA .A .F a r o o q u id e s c ri b e
in a comprehensive review how lipid-derived factors are
able to induce cellular stress and inﬂammation, which may
be involved in PD pathogenesis. In line with this, M. Liu
and G. Bing show in their revision how lipopolysaccharide
(LPS), a cell-wall component of Gram-negative bacteria and
prototypical inﬂammogen, induces dopaminergic cell death
indicating that the inﬂammatory response is by itself detri-
mental. Importantly, inﬂammation-induced toxicity seems
to be highly speciﬁc for dopaminergic cells and with very
special distinctiveness in some dopaminergic areas. In fact,
V. Roca et al. nicely described, in their review, the unique
susceptibility to inﬂammation of the Substantia Nigra, the
prime locus of dopaminergic cell death in PD.
Ontheotherhand,C.C.FerrariandR.Tarellidescribein
theircompletestudyhowsystemicinﬂammationmayimpact2 Parkinson’s Disease
central inﬂammation and dopaminergic cell death. Then,
they explore the possibility that peripheral inﬂammation
could be a contributing factor in PD development. This view
is further complemented by the review from A. Machado et
al., which gives a diﬀerent perspective of this particular topic
but focused on studies performed in animal models of PD.
Finally, in a last series of review, authors consider new
perspectives and therapeutic targets to avert toxic inﬂam-
mation in PD. First, A. R. Carta et al. discuss an emerging
strategy to block neuroinﬂammation in PD using PPAR-γ
agonists. This is particularly interesting in light of the above
discussion since ibuprofen but not aspirin or acetaminophen
has been shown to display PPAR-γ agonistic activity. P. M.
Flood et al. proposed new ways for targeting NF-kB through
IKK complex inhibition, a promising route that may be a
useful approach in a close future in the treatment of PD.
Finally, in a last review article, A. Zinger et al. describe how
the kynurenine pathway, a metabolic pathway involved in the
production of nicotinamide adenine dinucleotide, may be
critically involved in the neuroinﬂammatory process in PD
and how this pathway could be controlled for therapeutic
purposes.
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